Iterum Therapeutics plc received a delisting determination letter from Nasdaq on February 24, 2026, due to failure to maintain a minimum bid price of $1.00 per share. The company requested a hearing before an independent Nasdaq Hearings Panel on March 3, 2026, which automatically stays the delisting action. Iterum also does not meet Nasdaq's minimum market value of listed securities of $35 million, minimum shareholders' equity, or net income standards. The company has until June 9, 2026, to regain compliance with the minimum market value requirement. Iterum is evaluating corporate, strategic, and financial alternatives, including the possibility of a wind-down, bankruptcy, liquidation, or sale of assets, given its limited ability to raise additional capital.